Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Paper
  • Published:

Local and distant transfection of mdx muscle fibers with dystrophin and LacZ genes delivered in vivo by synthetic microspheres

Abstract

Patterns of dystrophin and β-galactosidase expression were examined in mdx mice after i.m. injections of synthetic microspheres (MF-2) loaded with full-length (pHSADy) or mini-dystrophin gene (pSG5dys) cDNA plasmid constructs or with LacZ marker gene (pCMV-LacZ). A single injection of 25 μg pHSADy into quadriceps femoris muscle resulted in 6.8% of dystrophin positive myofibers (DPM) in a given muscle; 8.4% of DPM in glutaeus muscle and 4.3% of DPM in quadriceps femoris muscle of contralateral limb on day 21 after exposure compared with only 0.6% DPM in intact (non-injected) mdx mice. A high proportion of DPM (17.6% and 10.8%, respectively) was registered in both injected and contralateral muscles after mini- gene cDNA administration. MF-2/dystrophin cDNA par- ticles were detected by FISH analysis in about 60–70% of myofiber nuclei in muscles of injected and contralateral limbs 7 days after application. The presence of human dystrophin cDNA and its products in all skeletal muscles and in different internal organs was proven by PCR and RT-PCR analysis. Patches of β-galactosidase expression were abundant in injected muscle, and frequent in the contralateral and other skeletal muscles as well as in diaphragm, heart and lungs. High levels of dystrophin cDNA expression, and an efficient distant transfection effect with preferential intranuclei inclusion of MF-2 vehicle, are very encouraging for the development of a new constructive strategy in gene therapy trials of DMD.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  1. Emery AEH . Duchenne Muscular Dystrophy, 2nd edn Oxford Monograph on Medical Genetics 24: Oxford University Press: Oxford 1993 p 157

    Google Scholar 

  2. Partridge TA . Models of dystrophinopathy, pathological mechanisms and assessment of therapies. In: Brown SC, Lucy JA (eds) Dystrophin: Gene, Protein and Cell Biology Cambridge University Press: Cambridge 1997 pp 310–331

    Google Scholar 

  3. Engel AG, Yamamoto M, Fischbeck KH . Dystrophinopathies. In: Engel AG, Franzini-Armstrong C (eds) Myology McGraw-Hill: New York 1994 pp 1133–1187

    Google Scholar 

  4. Clemens PR et al. In vivo muscle gene transfer of full-length dystrophin with an adenoviral vector that lacks all viral genes Gene Therapy 1996 3: 965–972

    CAS  PubMed  Google Scholar 

  5. Lochmuller H et al. Transient immunosuppression by FK506 permits a sustained high-level dystrophin expression after adenovirus-mediated dystrophin minigene transfer to skeletal muscles of adult dystrophic (mdx) mice Gene Therapy 1996 3: 706–716

    CAS  PubMed  Google Scholar 

  6. Fassati A, Murphy S, Dickson G . Gene therapy of Duchenne muscular dystrophy Adv Genet 1997 35: 117–153

    Article  CAS  PubMed  Google Scholar 

  7. Budker V et al. The efficient expression of intravascularly delivered DNA in rat muscles Gene Therapy 1998 5: 272–276

    CAS  PubMed  Google Scholar 

  8. Dodds E et al. Lipofection of cultured mouse muscle cells: a direct comparison of Lipofectamine and DOSPER Gene Therapy 1998 5: 542–551

    Article  CAS  PubMed  Google Scholar 

  9. Vitiello L et al. Condensation of plasmid DNA with polylysine improves liposome-mediated gene transfer into established and primary muscle cells Gene Therapy 1996 3: 396–404

    CAS  PubMed  Google Scholar 

  10. Baranov V et al. Human dystrophin gene expression in mdx muscles after in vivo ballistic transfection, application of synthetic oligopeptide complexes and cationic liposomes In: NATO ASI, Subseries M 1997 105: 219–223

    Google Scholar 

  11. Zelenin V, Tarasenko O, Kolesnikov VA et al. Bacterial β-galactosidase and human dystrophin genes are expressed in mouse skeletal muscle fibers after ballistic transfection FEBS Lett 1997 414: 319–322

    Article  CAS  PubMed  Google Scholar 

  12. Mathiowitz E, Jacob JS, Jong YS et al. Biologically erodable microspheres as potential oral drug delivery system Nature 1997 386: 410–414

    Article  CAS  PubMed  Google Scholar 

  13. Walsh S et al. Simultaneous delivery of drugs and genes by gelatin nanospheres Pediatric Pulmonology 1997 (Suppl. 14): 255–257

    Google Scholar 

  14. Bockhold KJ, Rosenblatt JD, Partridge TA . Aging normal and dystrophic muscle: analysis of myogenicity in cultures of living single fibers Muscle Nerve 1998 21: 173–183

    Article  CAS  PubMed  Google Scholar 

  15. Feero WG et al. Selection and use of ligands for receptor-mediated gene delivery to myogenic cells Gene Therapy 1997 4: 664–674

    Article  CAS  PubMed  Google Scholar 

  16. Cox GA et al. Overexpression of dystrophin in transgenic mdx mice eliminated dystrophic symptoms without toxicity Nature 1993 364: 725–729

    Article  CAS  PubMed  Google Scholar 

  17. Yanagihara I et al. Expression of full-length human dystrophin cDNA in mdx mouse muscle by HVJ-liposome injection Gene Therapy 1996 3: 549–553

    CAS  PubMed  Google Scholar 

  18. Skarli M et al. Myosin regulatory elements as vector for gene transfer by intramuscular injection Gene Therapy 1998 5: 514–520

    Article  CAS  PubMed  Google Scholar 

  19. Liu F, Qi H, Huang L, Liu D . Factors controlling the efficiency of cationic lipid-mediated transfection in vivo via intravenous administration Gene Therapy 1997 4: 517–523

    Article  CAS  PubMed  Google Scholar 

  20. Coonrod A, Li F-Q, Horwitz M . On the mechanism of DNA transfection: efficient gene transfer without viruses Gene Therapy 1997 4: 1313–1321

    Article  CAS  PubMed  Google Scholar 

  21. Wells D, Wells K, Asante EA et al. Expression of human full length and mini-dystrophin in transgenic mdx mice: implication for gene therapy of Duchenne muscular dystrophy Hum Mol Genet 1995 3: 1245–1250

    Article  Google Scholar 

  22. Roberts RG, Barby TFM, Manner E et al. Direct detection of dystrophin gene rearrangements by analysis of dystrophin mRNA in peripheral blood lymphocytes Am J Hum Genet 1991 49: 298–310

    CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The authors are grateful to ‘Biosystem XXI, St Petersburg, Russia for the original polymeric vehicle, to Dr Caroline Sewry and Dr Peter Strong (Hammersmith Hospital, London, UK) for the generous gift of P6 antibodies, Professor G Dickson (Royal Holloway University, London, UK) and Dr F Mavilio (TIGET, Milano, Italy) for dystrophin cDNA constructs. Personal gratitude to Professor T Partridge (Hammersmith Hospital, London, UK) for the stock of mdx mice, as well as permanent interest in this work and helpful constructive comments during manuscript preparation. This work was partly supported by the Russian State Program ‘Human Genome’ (grant 48/95).

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Baranov, A., Glazkov, P., Kiselev, A. et al. Local and distant transfection of mdx muscle fibers with dystrophin and LacZ genes delivered in vivo by synthetic microspheres. Gene Ther 6, 1406–1414 (1999). https://doi.org/10.1038/sj.gt.3300954

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.gt.3300954

Keywords

This article is cited by

Search

Quick links